cas 19748-66-4|| where to buy 1-(3-HYDROXYPROPYL)-PYRROLIDINE

製品名:1-(3-HYDROXYPROPYL)-PYRROLIDINE

IUPAC Name:3-(pyrrolidin-1-yl)propan-1-ol

包装単位	有効在庫	価格（USD）
CM101545-10g	in stock	ǊǊ
CM101545-25g	in stock	ŹŉĽ
CM101545-100g	in stock	ǤǊǤ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19748-66-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:19748-66-4; 分子式:C7H15NO; 融点:-; SMILESコード:OCCCN1CCCC1; 密度:

: カタログ番号:CM101545; 分子量:129.2; 沸点:216.9°C at 760 mmHg; MDL番号:MFCD01687769; 保管方法:Store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.